PL3326645T3 - Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM - Google Patents

Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM

Info

Publication number: PL3326645T3
Authority: PL; Poland
Prior art keywords: differences; svcam; alpha; methods; correlating
Prior art date: 2010-10-25

Application number

PL17192860T

Other languages

English (en)

Inventor

Alissa A. Chackerian

Original Assignee

Biogen Ma Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-25

Filing date

2011-10-24

Publication date

2020-09-21

2011-10-24 Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.

2020-09-21 Publication of PL3326645T3 publication Critical patent/PL3326645T3/pl

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)

PL17192860T 2010-10-25 2011-10-24 Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM PL3326645T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US40635810P	2010-10-25	2010-10-25
US40636510P	2010-10-25	2010-10-25
EP11838481.7A EP2632492B1 (en)	2010-10-25	2011-10-24	METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
PCT/US2011/057519 WO2012061074A1 (en)	2010-10-25	2011-10-24	METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
EP17192860.9A EP3326645B1 (en)	2010-10-25	2011-10-24	Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels

Publications (1)

Publication Number	Publication Date
PL3326645T3 true PL3326645T3 (pl)	2020-09-21

Family

ID=46024768

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL20162844.3T PL3722808T3 (pl)	2010-10-25	2011-10-24	Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam
PL17192860T PL3326645T3 (pl)	2010-10-25	2011-10-24	Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL20162844.3T PL3722808T3 (pl)	2010-10-25	2011-10-24	Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam

Country Status (18)

Country	Link
US (3)	US20130337470A1 (pl)
EP (3)	EP2632492B1 (pl)
JP (2)	JP5847188B2 (pl)
AU (4)	AU2011323820A1 (pl)
CA (1)	CA2816016A1 (pl)
CY (1)	CY1123060T1 (pl)
DK (2)	DK3326645T3 (pl)
ES (3)	ES2800066T3 (pl)
FI (1)	FI3722808T3 (pl)
HR (2)	HRP20241666T1 (pl)
HU (2)	HUE069385T2 (pl)
LT (2)	LT3326645T (pl)
PL (2)	PL3722808T3 (pl)
PT (2)	PT3722808T (pl)
RS (2)	RS66261B1 (pl)
SI (2)	SI3722808T1 (pl)
SM (2)	SMT202400498T1 (pl)
WO (1)	WO2012061074A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2011323820A1 (en)	2010-10-25	2013-05-23	Biogen Ma Inc.	Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels
EP3227685A1 (en) *	2014-12-02	2017-10-11	Nestec S.A.	Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
TW202504919A (zh)	2023-05-30	2025-02-01	美商派拉岡醫療公司	α4β7整合素抗體組合物及使用方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5338689A (en)	1987-08-24	1994-08-16	Stiftung Fur Diagnostische Forschung	Method and card for detecting antigens and/or antibodies
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5730978A (en)	1989-09-01	1998-03-24	Fred Hutchinson Cancer Research Center	Inhibition of lymphocyte adherence with α4β1-specific antibodies
US7238668B1 (en)	1989-09-01	2007-07-03	Fred Hutchinson Cancer Research Center	Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US6033665A (en)	1989-09-27	2000-03-07	Elan Pharmaceuticals, Inc.	Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5260210A (en)	1989-09-27	1993-11-09	Rubin Lee L	Blood-brain barrier model
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
GB9206318D0 (en)	1992-03-24	1992-05-06	Cambridge Antibody Tech	Binding substances
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5858657A (en)	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
DE69230142T2 (de)	1991-05-15	2000-03-09	Cambridge Antibody Technology Ltd.	Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en)	1991-05-15	2001-05-01	Cambridge Antibody Technology Ltd.	Methods for producing members of specific binding pairs
LU91067I2 (fr)	1991-06-14	2004-04-02	Genentech Inc	Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5224539A (en)	1991-06-14	1993-07-06	Coen Company, Inc.	Cooling system for air heaters and the like
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5885793A (en)	1991-12-02	1999-03-23	Medical Research Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5872215A (en)	1991-12-02	1999-02-16	Medical Research Council	Specific binding members, materials and methods
US5871734A (en)	1992-01-13	1999-02-16	Biogen, Inc.	Treatment for asthma with VLA-4 blocking agents
US5932214A (en)	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
ATE199392T1 (de)	1992-12-04	2001-03-15	Medical Res Council	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0678122B1 (en)	1993-01-12	1999-07-28	Biogen, Inc.	Recombinant anti-vla4 antibody molecules
CA2155303C (en)	1993-02-09	2010-04-20	Linda C. Burkly	Treatment for insulin dependent diabetes
US7435802B2 (en)	1994-01-25	2008-10-14	Elan Pharaceuticals, Inc.	Humanized anti-VLA4 immunoglobulins
US5840299A (en)	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9406974D0 (en)	1994-04-08	1994-06-01	Pharmaceutical Proteins Ltd	Transgenic production
BE1008817A6 (fr)	1994-10-28	1996-08-06	Univ Bruxelles	Procede d'obtention d'adn bicatenaire membranaire humain, produit obtenu par ce procede et trousse de diagnostic le contenant.
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
GB9712818D0 (en)	1996-07-08	1997-08-20	Cambridge Antibody Tech	Labelling and selection of specific binding molecules
DE19647381A1 (de)	1996-11-15	1998-05-20	Hoechst Ag	Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en)	1996-11-15	1998-05-25	Hoechst Ag	Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
US5965356A (en)	1997-01-31	1999-10-12	University Of Maryland, Baltimore	Herpes simplex virus type specific seroassay
US6489300B1 (en) *	1997-07-31	2002-12-03	Eugene D. Thorsett	Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19741235A1 (de)	1997-09-18	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de)	1997-09-23	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de)	1997-11-19	1999-05-20	Hoechst Marion Roussel De Gmbh	Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
ES2321994T3 (es) *	1998-05-13	2009-06-15	Genentech, Inc.	Diagnostico y tratamiento de trastornos hepaticos.
DE19821483A1 (de)	1998-05-14	1999-11-18	Hoechst Marion Roussel De Gmbh	Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19922462A1 (de)	1999-05-17	2000-11-23	Aventis Pharma Gmbh	Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6756378B2 (en)	1999-06-30	2004-06-29	Pharmacopeia Drug Discovery, Inc.	VLA-4 inhibitor compounds
CN1413210A (zh)	1999-12-28	2003-04-23	辉瑞产品公司	用于治疗炎症、自身免疫性疾病和呼吸系统疾病的vla－4依赖性细胞结合的非肽基抑制剂
AU2001287000A1 (en) *	2000-09-01	2002-03-13	The Center For Blood Research, Inc.	Modified polypeptides stabilized in a desired conformation and methods for producing same
DE10111877A1 (de)	2001-03-10	2002-09-12	Aventis Pharma Gmbh	Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de)	2001-08-01	2003-02-13	Aventis Pharma Gmbh	Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
ES2531852T3 (es)	2002-02-25	2015-03-20	Biogen Idec Ma Inc.	Administración de agentes para el tratamiento de la inflamación
EP2484381A1 (en)	2003-01-24	2012-08-08	Elan Pharmaceuticals Inc.	Composition for a treatment of demyelinating diseases and paralysis by administration of remyelinating agents
AU2004210679A1 (en)	2003-02-10	2004-08-26	Elan Pharmaceuticals, Inc.	Immunoglobulin formulation and method of preparation thereof
EP2394652A3 (en)	2004-02-06	2012-10-24	Elan Pharmaceuticals Inc.	Methods and compositions for treating tumors and metastatic disease
MY162179A (en)	2004-04-01	2017-05-31	Elan Pharm Inc	Steroid sparing agents and methods of using same
AU2005231467A1 (en)	2004-04-01	2005-10-20	Elan Pharmaceuticals, Inc.	Steroid sparing agents and methods of using same
US7196112B2 (en)	2004-07-16	2007-03-27	Biogen Idec Ma Inc.	Cell adhesion inhibitors
MX2007010971A (es)	2005-03-08	2007-09-19	Pharmacia & Upjohn Co Llc	Composiciones de anticuerpo anti-citla-4.
US8124350B2 (en) *	2005-04-04	2012-02-28	Biogen Idec Ma Inc.	Methods and products for evaluating an immune response to a therapeutic protein
WO2007100770A2 (en)	2006-02-28	2007-09-07	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007103112A2 (en)	2006-03-03	2007-09-13	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with natalizumab
CA2708262A1 (en)	2007-12-07	2009-06-18	Elan Pharmaceuticals, Inc.	Methods and compositions for treating liquid tumors
CA2723614C (en) *	2008-05-16	2015-07-14	Genentech, Inc.	Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2009141786A2 (en)	2008-05-21	2009-11-26	Piramal Life Sciences Limited	Anti-inflammatory compounds
WO2010053316A2 (en)	2008-11-06	2010-05-14	Snu R&Db Foundation	New use of sixth immunoglobulin-like domain of vcam-1
NZ577731A (en) *	2009-06-16	2010-08-27	Innate Therapeutics Ltd	Compositions and methods for treatment of multiple sclerosis
WO2011137418A1 (en) *	2010-04-30	2011-11-03	Elan Pharmaceuticals, Inc.	Selective integrin inhibitors
AU2011323820A1 (en)	2010-10-25	2013-05-23	Biogen Ma Inc.	Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels

2011
- 2011-10-24 AU AU2011323820A patent/AU2011323820A1/en not_active Abandoned
- 2011-10-24 EP EP11838481.7A patent/EP2632492B1/en active Active
- 2011-10-24 SI SI201132120T patent/SI3722808T1/sl unknown
- 2011-10-24 CA CA2816016A patent/CA2816016A1/en active Pending
- 2011-10-24 EP EP20162844.3A patent/EP3722808B1/en active Active
- 2011-10-24 ES ES17192860T patent/ES2800066T3/es active Active
- 2011-10-24 DK DK17192860.9T patent/DK3326645T3/da active
- 2011-10-24 WO PCT/US2011/057519 patent/WO2012061074A1/en active Application Filing
- 2011-10-24 LT LTEP17192860.9T patent/LT3326645T/lt unknown
- 2011-10-24 PL PL20162844.3T patent/PL3722808T3/pl unknown
- 2011-10-24 DK DK20162844.3T patent/DK3722808T3/da active
- 2011-10-24 US US13/881,520 patent/US20130337470A1/en not_active Abandoned
- 2011-10-24 LT LTEP20162844.3T patent/LT3722808T/lt unknown
- 2011-10-24 PL PL17192860T patent/PL3326645T3/pl unknown
- 2011-10-24 ES ES20162844T patent/ES2997080T3/es active Active
- 2011-10-24 HR HRP20241666TT patent/HRP20241666T1/hr unknown
- 2011-10-24 FI FIEP20162844.3T patent/FI3722808T3/fi active
- 2011-10-24 HU HUE20162844A patent/HUE069385T2/hu unknown
- 2011-10-24 HU HUE17192860A patent/HUE050713T2/hu unknown
- 2011-10-24 PT PT201628443T patent/PT3722808T/pt unknown
- 2011-10-24 SI SI201131889T patent/SI3326645T1/sl unknown
- 2011-10-24 PT PT171928609T patent/PT3326645T/pt unknown
- 2011-10-24 ES ES11838481.7T patent/ES2654820T3/es active Active
- 2011-10-24 SM SM20240498T patent/SMT202400498T1/it unknown
- 2011-10-24 EP EP17192860.9A patent/EP3326645B1/en active Active
- 2011-10-24 RS RS20241356A patent/RS66261B1/sr unknown
- 2011-10-24 RS RS20200712A patent/RS60565B1/sr unknown
- 2011-10-24 JP JP2013536701A patent/JP5847188B2/ja active Active
- 2011-10-24 SM SM20200380T patent/SMT202000380T1/it unknown
2015
- 2015-08-27 JP JP2015167690A patent/JP2015215363A/ja not_active Withdrawn
2016
- 2016-04-18 US US15/131,804 patent/US11079393B2/en active Active
2017
- 2017-03-10 AU AU2017201658A patent/AU2017201658B2/en active Active
2019
- 2019-06-12 AU AU2019204089A patent/AU2019204089A1/en not_active Abandoned
2020
- 2020-06-08 HR HRP20200920TT patent/HRP20200920T1/hr unknown
- 2020-06-17 CY CY20201100555T patent/CY1123060T1/el unknown
2021
- 2021-08-03 US US17/393,267 patent/US20220206012A1/en active Pending
- 2021-08-05 AU AU2021212059A patent/AU2021212059B2/en active Active

Also Published As

Publication number	Publication date
CY1123060T1 (el)	2021-10-29
HK1256157A1 (en)	2019-09-13
FI3722808T3 (fi)	2024-12-10
PT3326645T (pt)	2020-06-23
EP3326645A1 (en)	2018-05-30
AU2011323820A1 (en)	2013-05-23
US20220206012A1 (en)	2022-06-30
RS60565B1 (sr)	2020-08-31
JP2014500950A (ja)	2014-01-16
ES2654820T3 (es)	2018-02-15
US20160291035A1 (en)	2016-10-06
EP2632492B1 (en)	2017-10-04
HUE069385T2 (hu)	2025-03-28
HRP20200920T1 (hr)	2020-10-30
US20130337470A1 (en)	2013-12-19
HUE050713T2 (hu)	2020-12-28
AU2021212059B2 (en)	2025-02-27
ES2800066T3 (es)	2020-12-23
JP2015215363A (ja)	2015-12-03
WO2012061074A1 (en)	2012-05-10
SI3326645T1 (sl)	2020-09-30
DK3722808T3 (da)	2024-12-09
DK3326645T3 (da)	2020-06-15
EP2632492A1 (en)	2013-09-04
AU2019204089A1 (en)	2019-07-04
SMT202400498T1 (it)	2025-01-14
EP2632492A4 (en)	2014-04-02
AU2017201658A1 (en)	2017-03-30
CA2816016A1 (en)	2012-05-10
AU2021212059A1 (en)	2021-08-26
PL3722808T3 (pl)	2025-02-03
EP3722808B1 (en)	2024-09-11
EP3326645B1 (en)	2020-03-18
HRP20241666T1 (hr)	2025-02-14
SMT202000380T1 (it)	2020-09-10
SI3722808T1 (sl)	2025-02-28
ES2997080T3 (en)	2025-02-14
PT3722808T (pt)	2024-12-09
EP3722808A1 (en)	2020-10-14
LT3326645T (lt)	2020-08-10
US11079393B2 (en)	2021-08-03
RS66261B1 (sr)	2024-12-31
LT3722808T (lt)	2024-12-27
AU2017201658B2 (en)	2019-03-21
JP5847188B2 (ja)	2016-01-20

Publication	Publication Date	Title
EP2700061A4 (en)	2014-11-19	SYSTEMS AND METHOD FOR ANALYZING ENERGY CONSUMPTION
SG11201401913YA (en)	2014-09-26	Systems and methods for biological analysis
GB201420407D0 (en)	2014-12-31	Multi-cue object detection and analysis
IL227579B (en)	2019-05-30	Systems and methods for maximizing the use of samples
SG11201401016YA (en)	2014-04-28	Web inspection calibration system and related methods
SG11201401956XA (en)	2014-10-30	Undifferentiated cell detection method and complex carbohydrate detection method
PT2663864T (pt)	2019-06-21	Método de avaliação de imunodiversidade e seu uso
EP2629051A4 (en)	2015-07-22	THICKNESS MEASURING DEVICE AND MEASURING METHOD THEREFOR
EP2788794A4 (en)	2015-08-12	PERMEABILITY PREDICTION SYSTEMS AND METHODS INVOLVING QUADRATIC DISCRIMINANT ANALYSIS
EP2845003A4 (en)	2015-12-23	IMPROVED ANALYTIC METHOD AND SYSTEM
EP2705135A4 (en)	2015-05-06	SYSTEMS AND METHODS FOR ANALYZING BASOPHILES
IL222752A0 (en)	2012-12-31	Acoustic methods and systems for detecting terahertz radioation
ZA201208522B (en)	2014-08-27	Methods for measuring enzyme activity useful in determining cell viability in non-purified sapmles
EP2553115A4 (en)	2013-09-11	METHODS OF CULTURE AND ANALYSIS OF CELLS
SG11201401911XA (en)	2014-08-28	Systems and methods for biological analysis
EP2612256A4 (en)	2014-04-02	IMPLEMENTATION OF »WHAT-IF-ANALYSIS
EP2726813A4 (en)	2015-01-28	SURFACE MEASURING SYSTEM AND METHOD
EP2693195A4 (en)	2014-10-22	SPR SENSOR CELL, AND SPR SENSOR
EP2576809A4 (en)	2014-06-18	MEASURE A YEAST CONCENTRATION AND LIFE CAPABILITY
EP2640407A4 (en)	2014-07-09	PROCESS FOR INCREASING THE EXPRESSION AND ACTIVITY OF NEPRILYSIN
GB201207583D0 (en)	2012-06-13	Electrochemical detection method and related aspects
SMT202000380T1 (it)	2020-09-10	Metodi per determinare le differenze nell'attivita' di integrina alfa-4 correlando le differenze dei livelli di svcam e/o smadcam
EP2757363A4 (en)	2015-06-24	PLASMON SURFACE RESONANCE SENSOR CELL (SPR) AND SPR SENSOR
EP2725343A4 (en)	2015-03-11	SPR SENSOR CELL AND SPR SENSOR
PL2710950T3 (pl)	2018-01-31	Sposób oraz system pomiaru rozpraszania wewnątrzgałkowego